Synthesis and anticonvulsant activities of (R)-N-(4′-substituted) benzyl 2-acetamido-3-methoxypropionamides

Journal of Medicinal Chemistry

Volumn 53, Issue 3, 2010, Pages 1288-1305

  Salomé, Christophe ^a   Salomé Grosjean, Elise ^a   Park, Ki Duk ^a   Morieux, Pierre ^a   Swendiman, Robert ^a   DeMarco, Erica ^a   Stables, James P ^b   Kohn, Harold ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; N (2' FLUORO)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (2' TRIFLUOROMETHOXY)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (3' TRIFLUOROMETHOXY)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' AMINOMETHYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' CYANO)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' ETHYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' ETHYNYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' ISOPROPYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' METHOXYMETHYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' METHYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' PROPYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' TERTBUTYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' TRIFLUOROMETHOXY)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' TRIFLUOROMETHYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (4' VINYL)BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N (BIPHENYL 4 YL)METHYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N [4' (3 HYDROXYPROPYL)]BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N [4' (3 METHOXYPROP 1 YNYL)]BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N [4' (3 METHOXYPROPYL)]BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N [4' (3,3 DIMETHYLBUT 1 YNYL)]BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N [4' (PROP 1 YNYL)]BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N [4' (TERT BUTOXYCARBONYL)AMINOMETHYL]BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; N [4' (TRIMETHYLSILYL)ETHYNYL)]BENZYL 2 ACETAMIDO 3 METHOXYPROPIONAMIDE; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PROPIONAMIDE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRIC SHOCK; LATITUDE; MOUSE; NONHUMAN; RAT; SEIZURE; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ACETAMIDES; ANIMALS; ANTICONVULSANTS; CONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROSHOCK; HIPPOCAMPUS; KINDLING, NEUROLOGIC; MALE; MICE; MOLECULAR STRUCTURE; PENTYLENETETRAZOLE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; SERINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77249094565     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901563p     Document Type: Article

References (57)

1. Hauser, W. A.; Annegers, J. F.; Kurland, L. T. The prevalence of epilepsy in Rochester, Minnesota, 1940-80. Epilepsia 1991, 32, 429-445.
2. Evans, J. H. Post-traumatic epilepsy. Neurology 1962, 12, 665-674.
3. Lindsay, J. M. Genetics and epilepsy. Epilepsia 1971, 12, 47-54.
4. (a) Begley, C. E.; Annegers, J. F.; Lairson, D. R.; Reynolds, T. F.; Hauser, W. A. Cost of epilepsy in the United States:Amodel based on incidence and prognosis. Epilepsia 1994, 35, 1230-1243.
5. (b) Begley, C. E.; Famulari, M.; Annegers, J. F.; Lairson, D. R.; Reynolds, T. F.; Coan, S.; Dubinsky, S.; Newmark, M. E.; Leibson, C.; So, E. L.; Rocca, W. A. The cost of epilepsy in the United States: An estimate from population-based clinical and survey data. Epilepsia 2000, 41, 342-351.
6. (c) Begley, C. E.; Lairson, D. R.; Reynolds, T. F.; Coan, S. Early treatment cost in epilepsy and how it varies with seizure type and frequency. Epilepsy Res. 2001, 47, 205-215.
7. (a) Rogawski, M. A.; Porter, R. J. Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising development stage compounds. Pharmacol. Rev. 1997, 42, 223-286.
8. (b) McNamara, J. O. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed.; Hardman, J. G., Limbird, L. E., Eds.; McGraw-Hill: New York, 2001; Chapter 21, pp 521-547.
9. (c) Aiken, S. P.; Brown, W. M. Treatment of epilepsy: Existing therapies and future developments. Front. Biosci. 2000, 5, 124-152.
10. (a) Brodie, M. J.; Dichter, M. A. Antiepileptic drugs. N. Engl. J. Med. 1996, 334, 168-175.
11. (b) Dichter, M. A.; Brodie, M. J. New antiepileptic drugs. N. Engl. J. Med. 1996, 334, 1583-1590.
12. (a) McCorry, D.; Chadwick, D.; Marson, A. Current drug treatment of epilepsy in adults. Lancet Neurol. 2004, 3, 729-735.
13. (b) Duncan, J. S. The promise of new antiepileptic drugs. Br. J. Clin. Pharmacol. 2002, 53, 123-131.
14. (c) Bauer, J.; Reuber, M. Medical treatment of epilepsy. Expert Opin. Emerging Drugs 2003, 8, 457-467.
15. (d) Mattson, R. H.; Cramer, J. A.; Collins, J. F.; Smith, D. B. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. 1985, 313, 145-151.
16. Pellock, J. M.; Willmore, L. J. A rational guide to monitoring in patients receiving anticonvulsants. Neurology 1991, 41, 961-964.
17. Cortes, S.; Liao, Z.-K.; Watson, D.; Kohn, H. Effect of structural modification of the hydantoin ring on anticonvulsant activity. J. Med. Chem. 1985, 28, 601-606.
18. Conley, J. D.; Kohn, H. Functionalized D,L-amino acid derivatives. Potent new agents for the treatment to epilepsy. J. Med. Chem. 1987, 30, 567-574.
19. Kohn, H.; Conley, J. D. New antiepileptic agents. Chem. Br. 1988, 24, 231-234.
20. Kohn, H.; Conley, J. D.; Leander, J. D. Marked stereospecificity in a new class of anticonvulsants. Brain Res. 1988, 457, 371-375.
21. Kohn, H.; Sawhney, K. N.; LeGall, P.; Conley, J. D.; Robertson, D. W.; Leander, J. D. Preparation and anticonvulsant activity of a series of functionalized α-aromatic and α-heteroaromatic amino acids. J. Med. Chem. 1990, 33, 919-926.
22. Kohn, H.; Sawhney, K. N.; LeGall, P.; Robertson, D. W.; Leander, J. D. Preparation and anticonvulsant activity of a series of functionalized α-heteroatom-substituted amino acids. J. Med. Chem. 1991, 34, 2444-2452.
23. Kohn, H.; Sawhney, K. N.; Bardel, P.; Robertson, D. W.; Leander, J. D. Synthesis and anticonvulsant activities of α-heterocyclic α-acetamido-N-benzylacetamide derivatives. J. Med. Chem. 1993, 36, 3350-3360.
24. Bardel, P.; Bolanos, A.; Kohn, H. Synthesis and anticonvulsant activities of α-acetamido-N-benzylacetamide derivatives containing an electron-deficient α-heteroaromatic substituent. J. Med. Chem. 1994, 37, 4567-4571.
25. Kohn, H.; Sawhney, K. N.; Robertson, D. W.; Leander, J. D. Anticonvulsant properties of N-substituted α,α-diamino acid derivatives. J. Pharm. Sci. 1994, 83, 689-691.
26. Choi, D.; Stables, J. P.; Kohn, H. Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J. Med. Chem. 1996, 39, 1907-1916.
27. (a) Paruszewski, R.; Rostafinska-Suchar, G.; Strupinska, M.; Jaworski, P.; Stables, J. P. Synthesis and anticonvulsant activity of some amino acid derivative. Pharmazie 1996, 3, 145-148.
28. (b) Paruszewski, R.; Rostafinska-Suchar, G.; Strupinska, M.; Jaworski, P.; Winiecka, I.; Stables, J. P. Synthesis and anticonvulsant activity of some amino acid derivatives. Pharmazie 1996, 51, 212-215.
29. Levy, R. H.; Mattson, R.; Meldrum, B. Antiepileptic Drugs, 4th ed.; Raven Press: New York, 1995; Chapter 6.
30. The eudismic ratio it the ratio of activities of the two enantiomers: Lehmann, P. A. Quantifying stereoselectivity or how to choose a pair of shoes when you have two left feet. Trends Pharmacol. Sci. 1982, 3, 103-106.
31. Perucca, E.;Yasothan, U.;Clincke, G.; Kirkpatrick, P. Lacosamide. Nat. Rev. Drug Discovery 2008, 7, 973-974.
32. Stoehr, T.; Kupferberg, H. J.; Stables, J. P.; Choi, D.; Harris, R. H.; Kohn, H.; Walton, N.; White, H. S. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res. 2007, 74, 147-154.
33. Park, K. D.; Morieux, P.; Salomé, C.; Cotten, S. W.; Reamtong, O.; Eyers, C.; Gaskell, S. J.; Stables, J. P.; Liu, R.; Kohn, H. Lacosamide isothiocyanate-based agents: Novel agents to target and identify lacosamide receptors. J. Med. Chem. 2009, 52, 6897-6911.
34. Morieux, P.; Stables, J. P.; Kohn, H. Synthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivatives. Bioorg. Med. Chem. 2008, 16, 8968-8975.
35. LeTiran, A.; Stables, J. P.; Kohn, H. Design and evaluation of affinity labels of functionalized amino acid anticonvulsants. J. Med. Chem. 2002, 45, 4762-4773.
36. Kohn, H.; Robertson, D.; Leander, J. D. Unpublished results.
37. (a) Anderson, G. W.; Zimmerman, J. E.; Callahan, F. M. A reinvestigation of the mixed carbonic anhydride method of peptide synthesis. J. Am. Chem. Soc. 1967, 89, 5012-5017.
38. (b) Kunishima, M.; Kawachi, C.; Monta, J.; Terao, K.; Iwasaki, F.; Tani, S. 2-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium chloride: An efficient condensing agent leading to the formation of amides and esters. Tetrahedron 1999, 55, 13159-13170.
39. Chinchilla, R.; Najera, C. The Sonogashira reaction: A booming methodology in synthetic organic chemistry. Chem. Rev. 2007, 107, 874-922.
40. Scherrmann, M.-C.; Boutboul, A.; Estramareix, B.; Hoffmann, A. S.; Lubineau, A. Binding properties and esterase activity of monoclonal antibodies elicited against sucrose 6-heptylphosphonate. Carbohydr. Res. 2001, 334, 295-307.
41. Barral, K.; Moorhouse, A. D.; Moses, J. E. Efficient conversion of aromatic amines into azides: A one-pot synthesis of triazole linkages. Org. Lett. 2007, 9, 1809-1811.
42. For comparable procedures for resolving stereoisomers, see the following: (a) Weisman, G. R. In Asymmetric Synthesis-Analytical Methods; Morrison, J. D., Ed.; Academic Press: New York, 1983; Vol. 1, pp 153-171.
43. 1H NMR assay of the enantiomeric composition of amines and β-amino alcohols using O-acetyl mandelic acid as a chiral solvating agent. Tetrahedron 1987, 43, 5431-5456.
44. Stables, J. P.; Kupferberg, H. G. In Molecular and Cellular Targets for Antiepileptic Drugs; Avanzini, G., Tanganelli, P., Avoli, M., Eds.; John Libbey: London, 1977; pp 191-198.
45. Porter, R. J.; Cereghino, J. J.; Gladding, G. D.; Hessie, B. J.; Kupferberg, H. J.; Scoville, B.; White, B. G. Antiepileptic drug development program. Cleveland Clin. Q. 1984, 51, 293-305.
46. Dunham, N. W.; Miya, T.-S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. 1957, 46, 208-209.
47. Almenningen, A.; Bastiansen, O.; Fernholt, L.; Cyvin, B. N.; Cyvin, S. J.; Samdal, S. Structure and barrier of internal rotation of biphenyl derivatives in the gaseous state. Part 1. The molecular structure and normal coordinate analysis of normal biphenyl and perdeuteriated biphenyl. J. Mol. Struct. 1985, 128, 59-76.
48. Bastiansen, O.; Samdal, S. Structure and barrier of internal rotation of biphenyl derivatives in the gaseous state. Part 4. Barrier of internal rotation in biphenyl, perdeuteriated biphenyl and seven non-ortho-substituted halogen derivatives. J. Mol. Struct. 1985, 128, 115-125.
49. Topliss, J. G. Utilization of operational schemes for analog synthesis in drug design. J. Med. Chem. 1972, 15, 1006-1011.
50. (a) Lothman, E. W.; Williamson, J. M. Closely spaced recurrent hippocampal seizures elicit two types of heightened epileptogenesis: A rapidly developing, transient kindling and a slowly developing, enduring kindling. Brain Res. 1994, 649, 71-84.
51. (b) Morimoto, K.; Fahnestock, M.; Racine, R. J. Kindling and status epilepticus models of epilepsy: Rewiring the brain. Prog. Neurobiol. 2004, 73, 1-60.
52. Racine, R. J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32, 281-294.
53. (a) McNamara, J. O.; Byrne, M. C.; Dasheiff, R. M.; Fitz, J. G. The kindling model of epilepsy: A review. Prog. Neurobiol. 1980, 15, 139-159.
54. (b) Loscher, W.; Schmidt, D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res. 1998, 2, 145-181.
55. (c) McNamara, J. O. Development of new pharmacological agents for epilepsy: Lessons learned from the kindling model. Epilepsia 1989, 30 (Suppl. 1), S13-8.
56. Stables, J. P. NINDS ASP internal control data. Private communication.
57. Krall, R. L.; Penry, J. K.; Kupferberg, H. J.; Swinyard, E. A. Antiepileptic drug development: I. History and a program for progress. Epilepsia 1978, 19, 393-408.